SCHEMBL4064392

SCHEMBL4064392

COc1ccc(CNc2nc(C)cc3c2C(=O)OCC3)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CD38 P28907 1/20 0.44
JAK2 O60674 1/20 0.43
TYK2 P29597 1/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
PDE2A O00408 8/20 0.42
NPSR1 Q6W5P4 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
MAPT P10636 1/20 0.41
SLC2A1 P11166 1/20 0.41
CHRM4 P08173 1/20 0.41
APP P05067 1/20 0.40
ALDH1A1 P00352 2/20 0.39
HPGD P15428 2/20 0.39
NPC1 O15118 1/20 0.39
EGFR P00533 1/20 0.39
POLB P06746 1/20 0.39
NR2F2 P24468 1/20 0.39
KDM4E B2RXH2 1/20 0.39
THRB P10828 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4069309 0.88 RECQL (0.45) CD38MEN1KMT2APDE2AL3MBTL1
SCHEMBL4749409 0.87 JAK2 (0.42) JAK2TYK2MEN1KMT2ANPSR1
SCHEMBL4067001 0.86 JAK2 (0.41) JAK2TYK2MEN1KMT2APDE2A
SCHEMBL4071782 0.85 HRH1 (0.49) MEN1KMT2ANPSR1L3MBTL1MAPT
SCHEMBL4068685 0.85 JAK2 (0.41) JAK2TYK2MEN1KMT2ANPSR1
SCHEMBL4467820 0.83 TDP1 (0.40) JAK2TYK2PDE2ANPC1
SCHEMBL4251335 0.82 KCNH2 (0.49) MEN1KMT2APDE2AMAPTALDH1A1
SCHEMBL4749294 0.80 PTGDR (0.46) MEN1KMT2AMAPTAPPALDH1A1
SCHEMBL4243904 0.76 KDM4E (0.52) MEN1KMT2AL3MBTL1MAPTAPP
SCHEMBL4465084 0.74 KDM4E (0.49) MEN1KMT2ANPSR1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7601736-B2 Such as 3,4-dihydro-pyrano[3,4-c]pyridine-1-on; cytokine suppressive antiinflammatory drugs; analgesics SK CHEMICALS CO., LTD. (KR) 2009-10-13 US disclosed
EP-1706412-A4 NOVEL PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME SK CHEMICALS CO LTD (KR) 2009-03-18 EP disclosed
US-20070254909-A1 Novel Pyridine Derivatives, a Process for Their Preparation and a Pharmaceutical Composition Containing the Same SK CHEMICALS CO., LTD. (KR) 2007-11-01 US disclosed
EP-1706412-A1 NOVEL PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME SK Chemicals, Co., Ltd. (KR) 2006-10-04 EP disclosed
WO-2005063768-A1 NOVEL PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME SK CHEMICALS, CO., LTD. (KR) 2005-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254909-A1 Novel Pyridine Derivatives, a Process for Their Preparation and a Pharmaceutical Composition Containing the Same IL5, IL1B, P2RY4 CD38 311/4885JAK2 345/4885TYK2 233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.